A new article in Media Planet's supplement to The Guardian focused on the AMR Action Fund’s work and the challenges antimicrobial developers face in terms of raising capital. AMR Action Fund CEO Henry Skinner explained that the Fund is only a temporary stopgap and expressed concern that policymakers are not acting fast enough when it comes to enacting pull incentives.
"The AMR Action Fund is investing USD1 billion in companies that are developing urgently needed antibiotics targeting bacteria and fungi that the World Health Organization has deemed a priority because of the significant morbidity and mortality they bring. However, CEO Henry Skinner warns that the fund is only 'a partial and temporary stopgap' to the problem and is 'buying time' for policymakers to deliver more permanent market solutions."
Read the full article here.
